Impact of dosing regimen of custirsen, an antisense oligonucleotide, on safety, tolerability and cardiac repolarization in healthy subjects

RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform

(2010) C. Frank Bennett et al.   Annual Review of Pharmacology and Toxicology

Effects of clusterin over-expression on metastatic progression and therapy in breast cancer

(2010) Louise Flanagan et al.   BMC CANCER

Targeting the Cytoprotective Chaperone, Clusterin, for Treatment of Advanced Cancer

(2010) A. Zoubeidi et al.   CLINICAL CANCER RESEARCH

Efficacy and Safety of Mipomersen, an Antisense Inhibitor of Apolipoprotein B, in Hypercholesterolemic Subjects Receiving Stable Statin Therapy

(2010) Fatima Akdim et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Evaluation of Efficacy, Biodistribution, and Inflammation for a Potent siRNA Nanoparticle: Effect of Dexamethasone Co-treatment

(2009) Marc T Abrams et al.   MOLECULAR THERAPY

Fever Accentuates Transmural Dispersion of Repolarization and Facilitates Development of Early Afterdepolarizations and Torsade de Pointes Under Long-QT Conditions

(2008) Alexander Burashnikov et al.   Circulation-Arrhythmia and Electrophysiology

A Phase I Study of OGX-011, a 2'-Methoxyethyl Phosphorothioate Antisense to Clusterin, in Combination with Docetaxel in Patients with Advanced Cancer

(2008) K. N. Chi et al.   CLINICAL CANCER RESEARCH

Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin for the treatment of cancer

(2008) Kim N Chi et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS